BOSTON–(BUSINESS WIRE)–ZappRx, Inc., a digital health company that streamlines specialty medication prescribing, announced today that CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), has invested in the ZappRx platform, in order to add Duchenne to the ZappRx platform in 2019.
Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy that primarily affects boys. The genetic disease causes a progressive loss of muscle strength subsequent to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down. Approximately 15,000 US patients are affected with Duchenne, with a total of 300,000 patients worldwide. While there is currently no cure, there are a growing number of specialty pharmaceuticals emerging from clinical trials which may help significantly with disease management. ZappRx and CureDuchenne’s partnership will drive a more streamlined delivery of these life-changing drugs to Duchenne patients.
“We are delighted to have a partner to help us support a disease where we can have a significant impact. CureDuchenne’s investment and expertise will be instrumental in the strategic development of our neurology-specific platform,” said Zoë Barry, CEO and Founder, ZappRx. “We are proud to collaborate with an incredible organization like CureDuchenne. Together, we will be able to achieve our shared goal of improving the quality of life of patients living with rare diseases like Duchenne.”
Read the full article HERE.